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95% CI 0.86, 1.09), regardless of intensity of use; further, there 
was no association between use of ibuprofen or acetamino-
phen and PD.  Conclusion: Our findings provide no evidence 
for a protective effect of nonaspirin and aspirin NSAID pre-
scription drug use shortly before PD onset. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Inquiries into the role of neuroinflammation in Par-
kinson’s disease (PD) have coincided with increasing in-
terests in determining whether anti-inflammatory medi-
cations may be helpful in preventing PD. Today, it is well 
documented that neuroinflammatory processes contrib-
ute to the etiology of PD  [1, 2] . Experimental evidence and 
animal models in particular support a preventative role 
for nonsteroidal anti-inflammatory drugs (NSAIDs) in 
PD. For example, studies have demonstrated that an-
ti-inflammatory drugs such as acetylsalicylic acid are 
protective against MPTP-induced striatal dopamine de-
pletion in mice  [3, 4] . However pharmacoepidemiolog-
ic evidence remains equivocal; in fact, even two recent
meta-analyses summarizing all published data report 
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 Abstract 
 Background: Experimental evidence supports a preventa-
tive role for non-steroidal anti-inflammatory drugs (NSAIDs) 
in Parkinson’s disease (PD).  Methods: We investigated as-
sociations between use of aspirin, nonaspirin NSAIDs, and
acetaminophen and PD in a large population-based case-
control study using Danish health and pharmacy registries. 
We identified 1,931 PD cases reported in hospital or outpa-
tient clinic records who had received a primary diagnosis of 
PD between 2001 and 2006, and 9,651 age- and sex-matched 
controls from the Danish population register. Prescription 
medication use was documented in a pharmacy database 
covering all residents of Denmark since 1995.  Results: Ad-
justing for age, sex, use of cardiovascular disease drugs,
diagnosis of chronic pulmonary obstructive disorder, and 
Charlson comorbidity scores, and excluding prescriptions 
filled within 5 years before diagnosis, we found no evidence 
for an association between PD and either aspirin use (OR = 
0.97; 95% CI 0.82, 1.14) or nonaspirin NSAID use (OR = 0.97; 
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different conclusions  [5, 6] . The first meta-analysis con-
cluded that ibuprofen may be protective but NSAIDs as a 
class likely do not modify the risk of PD  [6] , while the 
second meta-analysis, which used more restrictive inclu-
sion criteria, stated that ‘regular and long-term use’ of 
non-aspirin NSAIDs reduces PD risk  [5] . The uncertain-
ty regarding a possible neuroprotective role for NSAIDs 
as a class or ibuprofen alone stems in large part from dif-
ferences in how previous human studies grouped or as-
certained their data, since medication type, timing of use 
prior to disease onset, and overall dose may be critical for 
assessing and interpreting their results. In order to ad-
dress some of these previous study limitations, we con-
ducted a large population-based case-control study based 
within the Danish registry that allowed us to ascertain a 
largely complete record of prescription NSAID and aspi-
rin use (including dose and duration of use) nationwide 
in Denmark starting in 1995.
 Methods 
 Study Population 
 Denmark’s National Health Service provides free and equal 
access healthcare to its residents. Each health services-related 
event is recorded in relevant national databases, including the 
Danish Hospital Register and the Danish Registry of Medical 
Products Statistic (the national prescription database). Both of 
these databases can be linked to the Danish Central Population 
Registry using a unique personal identification number assigned 
to all Danish citizens at birth or when awarded citizenship.
 We conducted a population-based case control study using 
this registry system. Cases were ascertained from the Danish 
Hospital Register that registered all hospitalizations with a PD 
diagnosis since 1977 and all clinic visits, including outpatient 
clinics, since 1994. We identified a total of 82,140 subjects, which 
comprised 13,695 cases who had received a primary PD diagnosis 
in the Danish Hospital Register in the period 1986–2006 and (1) 
had a valid personal identification number; (2) were over 35 years 
of age at the time of diagnosis, and (3) had not emigrated from 
Denmark, along with their 68,445 matched controls. To allow for 
a sufficiently long lag time between aspirin/NSAID medication 
use and PD diagnosis, we restricted the participants to all cases 
(and their matched controls) registered for the first time with a 
primary diagnosis of PD ( International Classification of Diseases, 
 10th revision, code G20) between January 2001 and December 
2006. In order to identify the earliest possible date of a PD diag-
nosis among these participants, we further refined the date of 
primary diagnosis of PD back to the first hospital or outpatient 
record that mentioned PD or the first recorded prescription of
a PD medication (anatomical therapeutic chemical, ATC, code 
N04B) since inception of the national prescription database 
(1995), whichever occurred earlier. If the backdated diagnosis (in-
dex) date occurred before 2001, the cases and their matched (5 or 
less) controls were excluded. This resulted in 13,123 total subjects 
(2,188 cases and 10,935 controls). We also excluded PD patients 
who had never received a PD drug prescription (ATC N04 AA01-
04, BA02-03, BB01, BC01-06, BD01-02, BX01-02), i.e. 257 cases 
and their respective 1,284 matched controls (1,541 total subjects), 
leaving us with a final total of 11,582 subjects (1,931 PD cases, 
9,651 controls). In sensitivity analyses, aimed at limiting the po-
tential for diagnostic bias, we excluded PD cases (and these cases’ 
matched controls) and controls diagnosed with any type of de-
mentia (both Alzheimer type and unspecified) or cerebrovascular 
disease before the index date (305 cases, 2,282 controls) or pa-
tients having taken neuroleptic medications (ATC N05A) within 
half a year of diagnosis (194 cases).
 Drug Use 
 Since 1995, the national prescription database has received 
data on dispensed prescriptions from all pharmacies in the coun-
try. Available data include the individual’s personal identification 
number, drug type by ATC code, and prescription dispensing 
date. All nonaspirin NSAIDs, except low-dose ibuprofen (200-mg 
tablets), can only be obtained with a prescription in Denmark. 
Over-the-counter ibuprofen use is estimated to account for 14% 
of total usage  [7] . Aspirin and acetaminophen can be obtained 
over the counter, but because costs for prescribed medications are 
at least partially reimbursed, long-term usage is thought to be 
largely confined to prescriptions and therefore captured in the 
national prescription database  [8] .
 For each study subject, we identified all prescriptions of as-
pirin (ATC codes B01AC06, N02BA01, N02BA51), nonaspirin 
NSAIDs (ATC group M01A), and acetaminophen (ATC code 
N02BE01) dispensed from 1995 until the index date. Because of 
the long preclinical period of PD, estimated to be 5–7 years  [9] , 
and because our case identification methods, despite our efforts 
to reduce this possibility likely still ascertained prevalent PD cas-
es, we advanced the index date (lagged) by 5 years for both cases 
and their matched controls in our primary analysis. Participants 
were defined as ‘ever’ users of the medications of interest if 2 or 
more prescriptions were recorded for them in the pharmacy da-
tabase during the relevant period of time and as nonusers other-
wise. Among users, we also created a variable for average annual 
use, which was the sum of the total number of prescriptions di-
vided by years of use prior to the index date.
 Statistical Analysis 
 We used unconditional logistic regression to calculate 95% 
confidence intervals (CI) and odds ratios (OR) for the following 
groups: aspirin, all nonaspirin NSAIDs, ibuprofen, and acetamin-
ophen. Acetaminophen, a common pain reliever that is not an 
NSAID, was included to assess whether potential associations re-
flected a nonspecific effect of analgesics. Analyses for average an-
nual use were based on the following four categories: less than 1 
prescription per year on average (reference group); 1–2 prescrip-
tions;  1 2–3 prescriptions, and 3+ prescriptions on average per 
year. In sensitivity analyses, we distinguished between aspirin 
prescribed in low dose (75–100 mg) as an anticoagulant or for
the prevention of cardiovascular disease (ATC code B01AC06) 
and aspirin prescribed as a pain killer (ATC codes N02BA01, 
N02BA51). We adjusted for age at diagnosis (continuous), sex, co-
morbidities registered before the lagged index date (using the 
Charlson index, a weighted index based on ICD codes for 19 
chronic disease categories that takes into account the number and 
seriousness of comorbid diseases)  [10] , chronic obstructive pul-
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monary disease (COPD) diagnosis (ICD codes = J42, J43, J44 and 
490.00, 491.00, 491.01, 491.03) identified in the Danish Hospital 
Register, and the use of cardiovascular disease drugs (ATC codes 
B01AA03, B01AA04, C01A-D, C07, C08, C09A-D) identified 
from the national prescription database prior to the lagged index 
date. We lagged both the Charlson index and COPD by 5 years to 
capture the general health status of subjects at the time of the 
lagged index date. A diagnosis of COPD was used as a proxy for a 
history of heavy smoking. The Danish population is primarily 
Caucasian, thus we did not adjust for race/ethnicity. We also strat-
ified some analyses by age at first diagnosis ( ! 60,  6 60 years) and 
sex. To further explore the possibility that NSAID use was trig-
gered by early symptoms of PD, in addition to our primary analy-
ses based on a 5-year lag period, we also performed unlagged and 
2-year lagged analyses.
 Results 
 As shown in  table 1 , our study population was mostly 
(58%) male, and on average 72.2 years (standard devia-
tion, SD, 10.5) of age. Approximately a quarter of cases 
and controls scored above zero on the Charlson index 5 
years prior to PD diagnosis (24.7 vs. 23.7%), and 24.7% of 
controls and 27.9% of cases had been prescribed medica-
tions for cardiovascular diseases, while COPD diagnoses 
were – as expected – somewhat higher in controls (2.1 vs. 
1.1% in cases). Before the index date, 34.6% of our study 
population had ever received two or more prescriptions 
for nonaspirin NSAIDs and 27.3% for aspirin (19% pre-
scribed as a low-dose anticoagulant and 12.1% as a pain 
killer). The recorded median length of time subjects re-
ceived non-aspirin NSAID prescriptions prior to the in-
dex date was 4.5 years (SD, 4.6) for PD cases and 4.9 years 
(SD, 4.9) for controls; and for aspirin it was 3.7 years (SD, 
2.9) among PD cases and 4.0 years (SD, 2.9) among con-
trols.
 Although we did not see an association between 5-year 
lagged prediagnosis aspirin use and PD ( table 2 ) among 
all subjects combined (OR = 0.97; 95% CI 0.82, 1.14), our 
data suggested a 22% risk reduction (OR = 0.78; 95% CI 
0.59, 1.04) for aspirin use in women. This inverse asso-
ciation between aspirin use and PD was strongest in 
women using an annual average of 2 or more aspirin pre-
scriptions but all 95% CI included the null value. Addi-
tionally, low-dose aspirin prescribed as an anticoagulant 
showed an inverse association with PD risk among wom-
en (OR = 0.69; 95% CI 0.48, 0.99). However, when exclud-
Table 1. C haracteristics of the Danish study population, 2001–2006
Cases (n = 1,931) C ontrols (n = 9,651)
total males
(n = 1,121)
females
(n = 810)
total males
(n = 5,603)
females
(n = 4,048) 
Age groupsa  1,931 71.9810.81 72.6810.21  9,651 71.9810.81 72.6810.21
30–40 15 10 (0.9) 5 (0.6) 68 45 (0.8) 23 (0.6)
40–50 59 39 (3.5) 20 (2.5) 298 194 (3.5) 104 (2.6)
50–60 183 109 (9.7) 74 (9.1) 921 548 (9.8) 373 (9.2)
60–70 438 258 (23.0) 180 (22.2) 2,190 1,309 (23.4) 881 (21.8)
70–80 753 420 (37.5) 333 (41.1) 3,769 2,100 (37.5) 1,669 (41.2)
80–90 455 274 (24.4) 181 (22.3) 2,279 1,356 (24.2) 923 (22.8)
>90 28 11 (1.0) 17 (2.1) 126 51 (0.9) 75 (1.9)
Charlson indexb       
0 1,454 828 (73.9) 626 (77.3) 7,365 4,215 (75.2) 3,150 (77.8)
1 251 163 (14.5) 88 (10.9) 1,245 791 (14.1) 454 (11.2)
≥2 226 130 (11.6) 96 (11.9) 1,041 597 (10.7) 444 (11.0)
COPD diagnosisb       
No 1,910 1,108 (98.8) 802 (99.0) 9,448 5,473 (97.7) 3,975 (98.2)
Yes 21 13 (1.2) 8 (1.0) 203 130 (2.3) 73 (1.8)
CVD drugsb       
No 1,393 812 (72.4) 581 (71.7) 7,269 4,249 (75.8) 3,020 (74.6)
Yes 538 309 (27.6) 229 (28.3) 2,382 1,354 (24.2) 1,028 (25.4)
Values are numbers of cases or controls with percentages in parentheses, unless otherwise specified.
1 Mean age 8 SD, years. a Age at diagnosis for cases. b Lagged by 5 years; categories represent test scores. 
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ing low-dose aspirin anticoagulant prescriptions, we not-
ed that associations for women were closer to the null 
value (OR = 0.90; 95% CI 0.62, 1.29). By contrast, exclud-
ing low-dose aspirin anticoagulant prescriptions resulted 
in an increased risk of PD with aspirin use among men 
(OR = 1.32; 95% CI 1.02, 1.71).
 We did not observe an association between nonaspirin 
NSAID use and PD ( table 3 ), even when stratifying by 
gender. We also did not observe any dose-response trend 
for average annual nonaspirin NSAID use ( table 3 ). Fur-
thermore, we observed no association between ever use 
of ibuprofen (5-year lag OR = 1.03; 95% CI 0.88, 1.22,  ta-
ble 4 ) or acetaminophen (5-year lag OR = 1.02; 95% CI 
0.86, 1.22, data not shown) and PD, with little variation 
for ibuprofen by gender and no trend with increasing 
dose ( table 4 ).
 In unlagged analyses, we noted a statistically signifi-
cant positive association for ever use of prescription aspi-
rin and PD overall (OR = 1.20; 95% CI 1.07, 1.34) which 
did not appear to differ by gender (male: OR = 1.11; 95% 
CI 0.95, 1.30; female: OR = 1.35; 95% CI 1.12, 1.62). More-
over, unlagged analyses revealed slightly increased OR 
for ever use of nonaspirin NSAIDs (OR = 1.17; 95% CI 
1.06, 1.29), ibuprofen (OR = 1.14; 95% CI 1.01, 1.28), and 
acetaminophen (OR = 1.47; 95% CI 1.30, 1.66).
 Our results did not measurably change when exclud-
ing cases and controls diagnosed with dementia or cere-
brovascular disease before the index date, or when ex-
Table 2. A ssociation between aspirin use and PD, 5-year laga
Cases
(n = 1,931)
Controls
( n = 9,651)
OR 95% CI
n % n %
Total population (n = 11,582)
Ever use
No 1,692 87.6 8,518 88.3 1.0 (ref.)
Yes 239 12.4 1,133 11.7 0.97 0.82, 1.14
Average annual prescriptions
<1 1,743 90.3 8,714 90.3 1.0 (ref.)
1 to <2 52 2.7 269 2.8 0.87 0.64, 1.21
2 to <3 44 2.3 229 2.4 0.86 0.62, 1.21
≥3 92 4.8 439 4.6 0.94 0.74, 1.20
Males (n = 6,724)
Ever use
No 956 85.3 4,888 87.2 1.0 (ref.)
Yes 165 14.7 715 12.8 1.09 0.89, 1.35
Average annual prescriptions
<1 992 88.5 5,006 89.3 1.0 (ref.)
1 to <2 31 2.8 167 3.0 0.84 0.57, 1.26
2 to <3 31 2.8 149 2.7 0.96 0.64, 1.43
≥3 67 6.0 281 5.0 1.08 0.80, 1.45
Females (n = 4,858)
Ever use
No 736 90.9 3,630 89.7 1.0 (ref.)
Yes 74 9.1 418 10.3 0.78 0.59, 1.04
Average annual prescriptions
<1 751 92.7 3,708 91.6 1.0 (ref.)
1 to <2 21 2.6 102 2.5 0.92 0.56, 1.49
2 to <3 13 1.6 80 2.0 0.71 0.39, 1.30
≥3 25 3.1 158 3.9 0.71 0.46, 1.10
a  Adjusting for age, sex, 5-year lagged COPD, 5-year lagged
use of CVD drugs, and 5-year lagged Charlson index.
Table 3. Association between nonaspirin NSAID use and PD, 
5-year laga
Cases
(n = 1,931)
Controls
(n = 9,651)
OR 95% CI
n % n %
Total population (n = 11,582)
Ever use
No 1,499 77.6 7,467 77.4 ref.
Yes 432 22.4 2,184 22.6 0.97 0.86, 1.09
Average annual use
<1 1,678 87.0 8,415 87.2 ref.
1 to <2 105 5.4 581 6.0 0.90 0.73, 1.11
2 to <3 60 3.1 254 2.6 1.18 0.89, 1.57
≥3 88 4.6 401 4.2 1.08 0.85, 1.37
Males (n = 6,724)
Ever use
No 892 79.6 4,485 80.0 ref.
Yes 229 20.4 1,118 20.0 1.01 0.86, 1.19
Average annual use
<1 991 88.4 5,004 89.3 ref.
1 to <2 62 5.5 308 5.5 1.01 0.76, 1.34
2 to <3 30 2.7 128 2.3 1.16 0.77, 1.73
≥3 38 3.4 163 2.9 1.16 0.81, 1.66
Females (n = 4,858)
Ever use
No 607 74.9 2,982 73.7 ref.
Yes 203 25.1 1,066 26.3 0.93 0.78, 1.10
Average annual use
<1 687 84.8 3,411 84.3 ref.
1 to <2 43 5.3 273 6.7 0.77 0.55, 1.08
2 to <3 30 3.7 126 3.1 1.20 0.79, 1.80
≥3 50 6.2 238 5.9 1.02 0.74, 1.41
a Adjusting for age, sex, 5-year lagged COPD, 5-year lagged 
cardiovascular disease, and 5-year lagged Charlson index.
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cluding PD patients who took neuroleptic medications 
(ATC N05A) within half a year of diagnosis. Addition-
ally stratified analyses by age at first diagnosis showed no 
difference in the effect estimates for any of the medica-
tion groups.
 Discussion 
 Our findings in this large Danish population-based 
case-control study provide little evidence for a protective 
role of prescription nonaspirin or aspirin NSAID use, or 
ibuprofen use, during a short preclinical period prior to 
PD diagnosis. The only statistically significant inverse as-
sociation with PD risk we observed was for women pre-
scribed low-dose aspirin as anticoagulants (OR = 0.69; 
95% CI 0.48, 0.99). Low-dose aspirin has been shown to 
be able to inhibit mammalian innate immune-mediated 
responses  [11] . Although experimental models show that 
aspirin has neuroprotective properties  [12] , two recent 
meta-analyses did not find any evidence of a protective 
effect of aspirin use prior to PD onset  [5, 6] . While aspirin 
is available over the counter in Denmark, long-term use 
is thought to be largely confined to prescriptions  [8] . 
Thus, we likely captured only long-term aspirin users in 
these prescription data.
 We also did not find an inverse association between 
nonaspirin NSAID use and PD, even among users with 
higher average annual use. This is inconsistent with re-
sults of a recent meta-analysis suggesting that longer-
term and regular nonaspirin NSAID users might be pro-
tected. Nonaspirin NSAIDs have heterogeneous pharma-
cological properties that may include the inhibition of 
cyclooxygenase action, or the synthesis of nitric oxide 
radicals, or inflammation-related transcription factors 
 [5, 13] . This heterogeneity might be masking a protective 
effect for specific NSAIDs with particular pharmacolog-
ical properties. In vitro studies have suggested that ibu-
profen in particular suppresses brain-related inflamma-
tion and lowers PD risk  [14, 15] , and a meta-analysis by 
Samii et al.  [6] , which combined results from three epide-
miologic studies, noted an inverse association for ibupro-
fen and PD. It is possible that nondifferential misclassifi-
cation of ibuprofen use, which was based on prescription 
use only, biased our effect estimates towards the null. 
However, a recent publication in this Danish cohort in-
vestigating the risk of PD patients with osteoarthritis, 
who are typically intensive users of NSAIDs, also sug-
gested no association between prolonged NSAID use and 
a risk of PD  [16] .
 Lagged analyses are important in our study given 
that our date of diagnosis does not likely capture the 
true date of PD onset. In unlagged analyses that includ-
ed prescriptions dispensed immediately prior to PD 
 diagnosis, we noted positive associations between PD 
and nonaspirin NSAIDs, ibuprofen, and acetaminophen 
use, which is consistent with observations that around 
the time of diagnosis, PD patients exhibit symptoms 
that may warrant pain medication use  [17] . Analyses 
that do not lag for an appropriate time prior to diagnosis 
are therefore likely to capture disease-related pain killer 
use. This protopathic bias would produce spurious pos-
itive associations which may explain previous positive 
study findings  [18, 19] .
Table 4. A ssociation between ibuprofen use and PD, 5-year laga
Cases
(n = 1,931)
Controls
( n = 9,651)
OR 95% CI
n % n %
Total population (n = 11,582)
Ever use 
No 1,736 89.9 8,711 90.3 ref.
Yes 195 10.1 940 9.7 1.03 0.88, 1.22
Average annual prescriptions
<1 1,825 94.5 9,185 95.2 ref.
1 to <2 47 2.4 224 2.3 1.05 0.76, 1.44
2 to <3 20 1.0 99 1.0 1.02 0.62, 1.64
≥3 39 2.0 143 1.5 1.35 0.94, 1.93
Males (n = 6,724) 
Ever use   
No 1,019 90.9 5,131 91.6 ref.
Yes 102 9.1 472 8.4 1.07 0.86, 1.35
Average annual prescriptions
<1 1,063 94.8 5,377 96.0 ref.
1 to <2 29 2.6 122 2.2 1.18 0.78, 1.79
2 to <3 11 1.0 49 0.9 1.12 0.58, 2.16
≥3 18 1.6 55 1.0 1.64 0.96, 2.81
Females (n = 4,858)
Ever use   
No 717 88.5 3,580 88.4 ref.
Yes 93 11.5 468 11.6 0.99 0.78, 1.25
Average annual prescriptions
<1 762 94.1 3,808 94.1 ref.
1 to <2 18 2.2 102 2.5 0.88 0.53, 1.46
2 to <3 9 1.1 50 1.2 0.90 0.44, 1.85
≥3 21 2.6 88 2.2 1.17 0.72, 1.90
a Adjusting for age, sex, 5-year lagged COPD, 5-year lagged 
cardiovascular disease, and 5-year lagged Charlson index.
D
ow
nl
oa
de
d 
by
: 
13
7.
10
8.
70
.6
 - 
1/
16
/2
01
7 
1:
12
:5
8 
PM
 Manthripragada  /Schernhammer  /Qiu  /
Friis  /Wermuth  /Olsen  /Ritz  
 Neuroepidemiology 2011;36:155–161 160
 Our study has several notable strengths. Relying on 
the Danish registry prescription records helped us avoid 
recall bias, which has been a problem in some previous 
studies. Additionally, the Danish registry system provid-
ed us with access to a large number of PD patients and 
controls. However, our study was still limited by a num-
ber of issues. First, the national prescription database did 
not extend back past 1995, thus, we only captured rela-
tively recent usage of prescription medications and were 
unable to examine different earlier life epochs during 
which regular usage may have occurred (such as middle 
age etc.). However, inflammation may perpetuate the de-
generation of dopaminergic neurons after an initial in-
sult and anti-inflammatory drugs may be most effective 
in halting neurodegeneration if taken early and/or con-
sistently throughout the inflammatory process. A study 
by Langston et al.  [20] showed that patients with MPTP-
induced parkinsonism exhibited the characteristics of 
chronic ongoing inflammation in the substantia nigra 
area as much as 16 years after initial exposure. Further-
more we lagged our primary analyses by 5 years to ac-
count for the possible inclusion of prevalent or preclinical 
cases, and thus we were only able to capture between 1 
and 7 years of prescription medications for all subjects. 
The time period we captured may not reflect a subject’s 
earlier NSAID use, underscoring that our findings only 
represent the impact of NSAID use at an older age, rela-
tively shortly before PD onset. Additionally, in our study 
we made the assumption that those redeeming a prescrip-
tion are in fact taking the medication, which seems to be 
a more valid assumption for those with repeated pre-
scriptions. We did not estimate the duration of use since 
this would have required additional assumptions. We 
lacked smoking data, so used COPD as a proxy for heavy 
smoking, although COPD is likely not a good proxy for 
smoking status. Lastly, we expect some nondifferential 
misclassification of PD diagnoses, which may have led us 
to miss important associations.
 In conclusion, our data do not provide strong evidence 
for a protective effect of nonaspirin – including ibupro-
fen – and aspirin NSAIDs, used shortly before diagnosis, 
in PD. Given evidence of chronic ongoing inflammation 
years before PD diagnosis, future studies should capture 
NSAID use decades before PD onset.
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